IPP 40 mg Powder
Prescription review online
A doctor will review your case and decide whether a prescription is medically appropriate.
Talk to a doctor about this medicine
Discuss your symptoms and possible next steps in a quick online consultation.
How to use Ipp
Contents of the leaflet
- Package Leaflet: Information for the Patient
- IPP, 40 mg, Powder for Solution for Injection
- What is IPP and what is it used for
- Important information before taking IPP
- How to take IPP
- Possible side effects
- If the patient experiences any of the following side effects, they should contact their doctor or the emergency department of the nearest hospital immediately:
- Severe skin changes (frequency not known: frequency cannot be estimated from the available data):
- Side effects detected in blood tests:
- Reporting side effects
- How to store IPP
- Contents of the pack and other information
Package Leaflet: Information for the Patient
IPP, 40 mg, Powder for Solution for Injection
Pantoprazole
Read the Package Leaflet Carefully Before Taking the Medication, as it Contains Important Information for the Patient.
- This package leaflet should be kept in case it needs to be read again.
- In case of any doubts, consult a doctor, pharmacist, or nurse.
- If the patient experiences any side effects, including those not listed in this package leaflet, they should inform their doctor, pharmacist, or nurse. See section 4.
Package Leaflet Contents:
- 1. What is IPP and what is it used for
- 2. Important information before taking IPP
- 3. How to take IPP
- 4. Possible side effects
- 5. How to store IPP
- 6. Contents of the pack and other information
Not sure if this medicine is right for you?
Discuss your symptoms and treatment with a doctor online.
1. What is IPP and what is it used for
IPP contains the active substance pantoprazole. Pantoprazole is a selective proton pump inhibitor, a medicine that reduces the amount of acid produced in the stomach. It is used to treat stomach and gut conditions caused by acid.
IPP is used in adults for the treatment of:
gastroesophageal reflux disease. Esophagitis (inflammation of the esophagus) with acid reflux;
gastric and duodenal ulcers;
Zollinger-Ellison syndrome and other conditions with excessive acid production.
2. Important information before taking IPP
When not to take IPP
if the patient is allergic to pantoprazole or any of the other ingredients of this medicine (listed in section 6);
if the patient is allergic to other proton pump inhibitors.
Warnings and precautions
Before taking IPP, the patient should discuss with their doctor, pharmacist, or nurse:
if the patient has severe liver problems. The patient should inform their doctor if they have ever had liver disease in the past. The doctor will monitor liver enzyme activity more closely. If activity increases, the medication should be discontinued;
if the patient is taking HIV protease inhibitors, such as atazanavir (used to treat HIV infection), at the same time as pantoprazole, as they should consult their doctor for advice;
if the patient is taking a proton pump inhibitor, such as pantoprazole, especially for more than a year, as it may slightly increase the risk of hip, wrist, and spine fractures, especially in patients with osteoporosis or those taking corticosteroids;
if the patient is going to have a specific blood test (chromogranin A determination);
In case of any of the following symptoms (which may indicate a more serious condition), the patient should inform their doctor before taking this medication:
unintentional weight loss;
vomiting, especially if it is repeated;
blood in the stool (black or tarry stools);
difficulty swallowing or pain when swallowing;
pale skin and feeling weak (anemia);
chest pain;
stomach pain;
severe and/or persistent diarrhea, as the use of this medication is associated with a small increased risk of infectious diarrhea.
Children and adolescents
IPP should not be used in children and adolescents under 18 years of age, as there is no data on its use in this age group.
IPP and other medications
The patient should tell their doctor or pharmacist about all medications they are currently taking or have recently taken, including those obtained without a prescription.
IPP may affect the effectiveness of other medications, so the patient should inform their doctor about taking:
medications such as ketoconazole, itraconazole, and posaconazole (used to treat fungal infections) or erlotinib (used to treat certain types of cancer), as IPP may inhibit the proper functioning of these and other medications;
warfarin and phenprocoumon, which can cause blood to thicken or thin; further testing may be necessary;
HIV medications, such as atazanavir;
methotrexate (used to treat rheumatoid arthritis, psoriasis, and cancer);
if the patient is taking methotrexate, their doctor may temporarily discontinue IPP, as it may increase methotrexate levels in the blood;
fluvoxamine (used to treat depression and other mental health conditions); in patients taking fluvoxamine, the doctor may reduce the dose;
rifampicin (used to treat infections);
St. John's Wort (Hypericum perforatum) used to treat mild depression.
Pregnancy, breastfeeding, and fertility
There is no sufficient data on the use of pantoprazole in pregnant women. Pantoprazole has been reported to pass into breast milk.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medication.
IPP can only be used during pregnancy or breastfeeding if the doctor considers the benefits to the mother outweigh the potential risks to the fetus or baby.
Driving and using machines
IPP has no or negligible influence on the ability to drive and use machines.
If the patient experiences side effects such as dizziness or vision disturbances, they should not drive or operate machinery.
IPP contains sodium
This medication contains less than 1 mmol (23 mg) of sodium per vial, which means it is essentially 'sodium-free'.
Started taking the medicine and have questions?
Discuss your symptoms and treatment with a doctor online.
3. How to take IPP
The daily dose of IPP is administered intravenously by a nurse or doctor over 2 to 15 minutes.
Recommended dose:
Treatment of gastric and duodenal ulcers and gastroesophageal reflux disease
One vial (40 mg pantoprazole) per day.
Long-term treatment of Zollinger-Ellison syndrome and other conditions with excessive acid production
Two vials (80 mg pantoprazole) per day.
The doctor may adjust the dose later based on the amount of acid produced.
If the doctor prescribes more than two vials (80 mg) per day, the patient will receive the medication in two equal doses. The doctor may recommend temporary use of a dose exceeding 4 vials (160 mg) per day. If rapid reduction of acid production is necessary, an initial dose of 160 mg (4 vials) should be sufficient to achieve the desired reduction.
Patients with liver impairment
If the patient has severe liver problems, they should receive a daily intravenous dose of only 20 mg (half a vial).
Use in children and adolescents
IPP should not be used in children and adolescents under 18 years of age.
Overdose
Doses are carefully checked by the nurse or doctor, so overdose is highly unlikely.
There are no known symptoms of overdose.
In case of any further doubts about the use of this medication, the patient should consult their doctor, pharmacist, or nurse.
4. Possible side effects
Like all medications, IPP can cause side effects, although not everybody gets them.
If the patient experiences any of the following side effects, they should contact their doctor or the emergency department of the nearest hospital immediately:
Severe allergic reactions (rare: may occur in less than 1 in 1000 people):swelling of the tongue and/or throat, difficulty swallowing, hives, difficulty breathing, allergic swelling of the face (Quincke's edema/anaphylaxis), severe dizziness with a very fast heartbeat and excessive sweating.
Severe skin changes (frequency not known: frequency cannot be estimated from the available data):
The patient may notice one or more of the following symptoms:
- -blistering of the skin with rapid deterioration of general health, ulcers in the eyes, nose, mouth/lips, or genitals, or increased sensitivity of the skin/skin rash, especially in areas exposed to the sun. Joint pain or flu-like symptoms, fever, swelling of the lymph nodes (e.g., in the armpits), and changes in blood test results may also occur.
- red spots or patches on the torso, often with blisters in the center, peeling of the skin, ulcers in the mouth, throat, nose, genitals, and eyes. The appearance of such a severe skin rash may be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
- widespread rash, high fever, and swollen lymph nodes (DRESS or drug hypersensitivity syndrome).
Other severe conditions (frequency not known):yellowing of the skin or whites of the eyes (severe liver damage, jaundice) or fever, rash, and swollen kidneys, sometimes with pain when urinating and pain in the lower back (severe kidney inflammation, which can progress to kidney failure).
Other side effects:
Common(may occur in less than 1 in 10 people)
inflammation of the vein wall and blood clot formation in the vein at the injection site, mild stomach polyps.
Uncommon(may occur in less than 1 in 100 people)
headache; dizziness; diarrhea; nausea; vomiting; feeling of fullness and bloating (gas); constipation; dry mouth; stomach pain and discomfort; skin rash; itching; feeling of weakness, fatigue, or general malaise; sleep disturbances; fractures in the hip, wrist, or spine.
Rare(may occur in less than 1 in 1000 people)
disturbances or complete loss of taste, vision disturbances such as blurred vision; hives; joint pain; muscle pain; changes in body weight; increased body temperature; high fever; swelling of the limbs (peripheral edema); allergic reactions; depression; breast enlargement in men.
Very rare(may occur in less than 1 in 10,000 people)
disorientation.
Frequency not known(frequency cannot be estimated from the available data)
hallucinations, confusion (especially in patients who have experienced these symptoms before); feeling of tingling, pricking, burning, or numbness; rash, which may be accompanied by joint pain; inflammation of the colon, causing persistent watery diarrhea.
Side effects detected in blood tests:
Uncommon(may occur in less than 1 in 100 people)
increased liver enzyme activity.
Rare(may occur in less than 1 in 1000 people)
increased bilirubin levels; increased fat levels in the blood; sudden decrease in the number of white blood cells in the blood, with high fever.
Very rare(may occur in less than 1 in 10,000 people)
decrease in platelet count, which may cause bleeding or easier bruising; decrease in white blood cell count, which may increase the risk of infections; abnormal decrease in the number of red and white blood cells and platelets.
Frequency not known(frequency cannot be estimated from the available data)
decrease in sodium, magnesium, calcium, or potassium levels in the blood (see section 2).
Reporting side effects
If the patient experiences any side effects, including those not listed in this package leaflet, they should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301/fax: +48 22 49 21 309/website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of this medication.
5. How to store IPP
The medication should be stored out of sight and reach of children.
Do not use this medication after the expiry date stated on the packaging after EXP.
The expiry date refers to the last day of the month stated.
Do not store above 25°C.
Vials should be stored in the outer packaging to protect from light.
Prepared solution should be used within 12 hours.
Prepared and diluted solution should be used within 12 hours.
From a microbiological point of view, the product should be used immediately. If not used immediately after preparation, it should not be stored for more than 12 hours at a temperature below 25°C. The user is responsible for the storage conditions before administration.
IPP should not be used if the appearance of the solution has changed (e.g., due to clouding or sediment formation).
The contents of the vial are for single use only. Any remaining product in the vial should be discarded.
Medications should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medications that are no longer needed. This will help protect the environment.
6. Contents of the pack and other information
What IPP contains
Active substance: one vial of IPP contains 45.11 mg of pantoprazole sodium sesquihydrate, equivalent to 40 mg of pantoprazole.
What IPP looks like and contents of the pack
IPP is a white or yellowish powder (powder for solution for injection) in glass vials with a red rubber stopper and an aluminum cap with a plastic protective cover.
The vials are packaged in cardboard boxes. Each box contains 1 or 10 glass vials.
Marketing authorization holder
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl, Austria
Manufacturer
Lek Pharmaceuticals d.d.
Verovškova 57
1526 Ljubljana, Slovenia
For more information about this medication and its names in other EU countries, please contact:
Sandoz Polska Sp. z o.o.
ul. Domaniewska 50 C
02-672 Warsaw
tel. 22 209 70 00
Date of last revision of the package leaflet:12/2024
Sandoz logo
----------------------------------------------------------------------------------------------------------------
Information intended for healthcare professionals only:
The ready-to-use solution is prepared by injecting 10 ml of 0.9% (9 mg/ml) sodium chloride injection into the vial containing the powder. The resulting solution should be colorless to pale yellow. The prepared solution can be administered directly or after mixing with 100 ml of 0.9% (9 mg/ml) sodium chloride injection or 5% (55 mg/ml) glucose solution for injection. Only glass or plastic containers should be used for dilution.
IPP should not be prepared or mixed with solutions other than those listed.
The prepared solution must be used within 12 hours. From a microbiological point of view, the product should be used immediately. If not used immediately after preparation, it should not be stored for more than 12 hours at a temperature below 25°C. The user is responsible for the storage conditions before administration.
IPP should be administered intravenously over 2 to 15 minutes.
The contents of the vial are for single use only. Any remaining product in the vial or with a changed appearance (e.g., due to clouding or sediment formation) should be discarded.
- Country of registration
- Dosage formPowder, 40 mg
- ATC codeA02BC02
- Active substance
- Prescription requiredYes
- Manufacturer
- ImporterLek Pharmaceuticals d.d.
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to IppDosage form: Tablets, 40 mgActive substance: pantoprazoleManufacturer: Adamed Pharma S.A.Prescription requiredDosage form: Tablets, 20 mgActive substance: pantoprazoleManufacturer: Adamed Pharma S.A. S.C. Terapia S.A.Prescription not requiredDosage form: Tablets, 20 mgActive substance: pantoprazoleManufacturer: Adamed Pharma S.A.Prescription required
Online doctors for Ipp
Discuss questions about Ipp, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Get Ipp Prescription Online
Fill in a 2-min form
Tell us your symptoms, history, and what medicine you're requesting.
Pick a doctor or let us assign
Choose a specialist or we'll match you with the next available doctor.
Doctor reviews your case
Usually within 30 minutes. They may ask follow-up questions via chat.
Collect from any pharmacy
Electronic prescription sent to your email — valid across Spain.
Frequently Asked Questions
Ipp requires a prescription in Poland. You can check with a doctor online whether this medicine may be appropriate for your situation.
The active ingredient in Ipp is pantoprazole. This information helps identify medicines with the same composition but different brand names.
Ipp is manufactured by Lek Pharmaceuticals d.d.. Pharmacy brands and packaging may differ depending on the distributor.
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether Ipp is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.
You can buy Ipp in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.
To obtain a prescription, you can use Oladoctor:
Other medicines with the same active substance (pantoprazole) include Anesteloc 40 mg, Anesteloc Max, Anesteloc. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
